title: Indications and options for systemic therapy in melanoma.
abstract: The management of unresectable metastatic melanoma has dramatically improved in recent years. Surgeons need to familiarize themselves with new drugs and the biology behind them, and ongoing clinical trials and new drugs in development for adjuvant therapy and treatment of metastatic disease.
authors.affiliation: Department of Cutaneous Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA; Department of Oncologic Sciences, USF Morsani College of Medicine, 12901 Bruce B. Downs Boulevard, Tampa, FL 33612, USA. Electronic address: vernon.sondak@moffitt.org.
authors.forename: Vernon K
authors.initials: VK
authors.lastname: Sondak
authors.affiliation: Department of Cutaneous Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA; Department of Oncologic Sciences, USF Morsani College of Medicine, 12901 Bruce B. Downs Boulevard, Tampa, FL 33612, USA.
authors.forename: Geoffrey T
authors.initials: GT
authors.lastname: Gibney
mesh_terms: D000465:Algorithms; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy / Q000379:methods; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007372:Interferons / Q000627:therapeutic use; D008545:Melanoma / Q000628:therapy*; D058990:Molecular Targeted Therapy / Q000379:methods; D012307:Risk Factors; D012878:Skin Neoplasms / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D007372:Interferons
keywords: Adjuvant therapy; Immunotherapy; Melanoma; Targeted therapy